Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility study

This publication has 4 references indexed in Scilit:

• Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
  Investigational New Drugs, 2005
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
  British Journal of Cancer, 2003
• Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status
  Lung Cancer, 2003